

**Table for basic characteristics of articles included in this review article as of July 2023**

N°	Article	Data collection period	No. of sites	No. of samples	Analyzed molecular marker of drug resistance	Quality level
1	Alker AP et al. 2008 [1]	2002	1	249	<i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
2	Antonia AL et al. 2014 [2]	2007	Unkown	180	<i>Pf</i> CRT	Moderate
3	Baraka V et al. 2017 [3]	2012-2014	1	37	<i>Pf</i> DHPS	Moderate
4	Baraka V et al. 2018 [4]	2012-2014	1	2265	<i>Pf</i> MDR1	Moderate
5	Cohuet S et al. 2006 [5]	2003-2004	3	458	<i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
6	Deutsch-Feldman M et al. 2019 [6]	2013-2014, 2007	Unkown	852	<i>Pf</i> DHFR, <i>Pf</i> CRT	Moderate
7	Kamau E et al. 2015 [7]	2013-2014	1	82	<i>Pf</i> K13	Moderate
8	Kayiba NK et al. 2021 [8]	2018-2019	1	844	<i>Pf</i> DHPS, <i>Pf</i> DHFR	Moderate
9	Leroy D et al. 2019 [9]	2014-2015	1	5	<i>Pf</i> K13	Moderate
10	Menard D et al. 2016 [10]	2009-2014	Unkown	1288	<i>Pf</i> K13	Moderate
11	Mens PF et al. 2008 [11]	2003-2004	1	78	<i>Pf</i> DHPS	Moderate
12	Miotto O et al. 2015 [12]	2009-2010	1	115	<i>Pf</i> K13	Moderate
13	Mobula L et al. 2009 [13]	2008	1	142	<i>Pf</i> CRT, <i>Pf</i> MDR1, <i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
14	Moriarty LF et al. 2021 [14]	2017-2018	5	523	<i>Pf</i> CRT, <i>Pf</i> K13, <i>Pf</i> MDR1	Moderate
15	Mvumbi DM et al. 2013[15]	2010	1	145	<i>Pf</i> CRT	Moderate
16	Mvumbi DM et al. 2017 [16]	2014	6	280	<i>Pf</i> K13	Moderate
17	Nkoli Mandoko P et al. 2018 [17]	2014-2015	2	2030	<i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
18	Nundu SS et al. 2022 [18]	2019	1	229	<i>Pf</i> K13, <i>Pf</i> MDR1, <i>Pf</i> DHFR, <i>Pf</i> DHPS, <i>Pf</i> CRT	Moderate
19	Ruh E et al. 2018 [19]	2014	1	48	<i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
20	Severini C et al. 2006 [20]	2000	1	27	<i>Pf</i> CRT	Moderate
21	Swarthout TD et al. 2006 [21]	2003	1	217	<i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
22	Taylor SM et al. 2014 [22]	2007	11	179	<i>Pf</i> DHPS	Moderate
23	Taylor SM et al. 2015 [23]	2007	3	151	<i>Pf</i> K13	Moderate
24	van Lenthe M et al. 2019 [24]	2017	4	1086	<i>Pf</i> DHFR, <i>Pf</i> DHPS	Moderate
25	Wilson PE et al. 2005 [25]	2002	1	56	<i>Pf</i> CRT	Moderate
26	Yobi DM et al. 2020a [26]	2017	10	1070	<i>Pf</i> K13	Moderate
27	Yobi DM et al. 2020b [27]	2017	10	1070	<i>Pf</i> CRT	Moderate
28	Yobi DM et al. 2021 [28]	2018-2019	6	474	<i>Pf</i> CRT, <i>Pf</i> K13, <i>Pf</i> MDR1	Moderate
29	Yobi DM et al. 2022 [29]	2019-2020	10	1087	<i>Pf</i> CRT, <i>Pf</i> K13	Moderate